This article contains content that is written like an advertisement .(June 2018) |
Abbreviation | IVI |
---|---|
Formation | October 9, 1997 |
Founder | United Nations Development Programme |
Type | International organization |
Purpose | Discover, develop, and deliver safe, effective, and affordable vaccines for global public health. |
Headquarters | Seoul, Republic of Korea |
Membership | 39 member states and the World Health Organization |
Director General | Jerome Kim, M.D. |
Budget | US$27 million(2017) [1] |
Staff | 210 |
Website | www |
The International Vaccine Institute (IVI) is a non-profit, autonomous international organization established with the mandate of making vaccines available to all. Collaborating closely with the global scientific community, public health entities, governments, and industry stakeholders, IVI focuses on vaccine research and deployment. This includes conducting new vaccine designs in laboratories, advancing vaccine development and assessment in real-world settings, and facilitating the sustainable integration of vaccines in regions where they are most urgently required.
Initially conceived as an initiative under the auspices of the United Nations Development Program (UNDP), IVI transitioned into a fully-independent international entity in 1997, with its headquarters situated in Seoul, Republic of Korea. IVI currently has a membership comprising 39 states, with 33 signatories and 23 parties, alongside the endorsement of the World Health Organization (WHO) through its Establishment Agreement. Distinctively, IVI is mandated to concentrate exclusively on vaccine research and deployment tailored to populations in developing areas, with particular emphasis on combating diseases with a serious impact on public health in these regions. [2]
In 1992, Dr. Seung-Il Shin, then Senior Health Advisor for the United Nations Development Program (UNDP), initiated a study to explore the feasibility of establishing an international institute devoted to vaccine research and development within the framework of the Children's Vaccine Initiative (CVI). [3]
Based on the results of Shin's feasibility study, the UNDP adopted a formal proposal to establish the International Vaccine Institute (IVI) in 1993. In 1994, following a call for proposals to host IVI in the Asia Pacific region, the UNDP and the Republic of Korea reached an agreement to host the center in Seoul. In 1995, UNDP opened an interim IVI office on the campus of Seoul National University, and the Institute began its initial work and organizational development. [4]
In 1995 and 1996, the UNDP and the South Korean government jointly developed the basic framework and Constitution of IVI. In order to establish IVI as an independent international organization, the UNDP and Korean government elected to establish the institute through an intergovernmental agreement of UN member states, as sanctioned in the Vienna Convention on the Laws of Treaties of 1969. [5]
On October 28, 1996, the IVI Establishment Agreement opened for signatures at the UN headquarters in New York City. Representatives from Bangladesh, Bhutan, Indonesia, Kazakhstan, Mongolia, the Netherlands, Panama, Republic of Korea, Romania, Thailand, Vietnam, Uzbekistan, and the World Health Organization were the first to sign the agreement, followed shortly thereafter by Senegal and Philippines. [6]
In 1997, more countries followed, with Brazil, China, Egypt, Israel, Jamaica, Kyrgyzstan, Myanmar, Nepal, Pakistan, Papua New Guinea, Peru, Sri Lanka, Sweden, Tajikistan, and Turkey signing the Agreement. [7]
On May 29, 1997, The IVI Establishment Agreement entered into force following the submission of instruments of ratification by South Korea, Sweden, and Uzbekistan. The IVI Establishment Agreement entered the United Nations Depository of Treaties under Chapter IX. HEALTH, section 3. [7]
On September 24, 1998, the IVI Headquarters Agreement was signed at a formal ceremony at UNDP headquarters by South Korea's Minister of Foreign Affairs and Trade, Hong Soon-Young and IVI Board Chairman, Dr. Barry Bloom. The Headquarters Agreement established IVI as a legal entity with diplomatic immunity in South Korea, becoming the first international organization to be headquartered in South Korea. In accordance with IVI's independent status, the Institute formally separated from the UNDP in 1998. [8]
The IVI headquarters building, located in Seoul National University's Research Park in Seoul, South Korea, was designed by a consortium consisting of Samwoo Architects of South Korea and Payette Associates of Boston, United States. Construction began in 1998 and was completed in 2003. The building houses laboratories, animal facilities, offices, an auditorium, and a library. A separate 1,300m² pilot plant facility, intended for the production of test lots of vaccines for training and evaluation purposes, was constructed but never completed due to a lack of funding. [9]
IVI's first major initiative, Diseases of the Most Impoverished (DOMI), was a program of research and technical assistance to accelerate the introduction of new vaccines against typhoid fever, cholera, and shigellosis into public health programs in developing countries. From 2000 to 2006, IVI's DOMI program carried out vaccination campaigns, disease surveillance, and research studies in Bangladesh, China, India, Indonesia, Mozambique, Pakistan, Thailand, and Vietnam. At the conclusion of the DOMI program, IVI synthesized the diverse epidemiological, clinical, economic, and behavioral findings of these studies in order to facilitate informed decision-making by policymakers at the national level on the use of vaccines against the diseases targeted by DOMI. The Bill and Melinda Gates Foundation was the primary funder of the DOMI program with a US$40 million contribution. [10] [11]
The DOMI Typhoid program was initiated to address the barriers of access to typhoid vaccines in the developing world and to accelerate the introduction of modern typhoid vaccines in countries where they were needed. DOMI Typhoid utilized the Vi-Polysaccharide (Vi-PS) vaccine because it is easily and inexpensively produced by manufacturers in developing countries, it is given in a single dose, and it is relatively thermostable. DOMI Typhoid operated in five study sites: Heichi, China; Kolkata, India; North Jakarta, Indonesia; Karachi, Pakistan; and Hue, Vietnam. From these sites, IVI experts conducted disease surveillance, disease burden studies, cost-of-illness studies, socio-behavioral studies, and vaccine demonstration projects. IVI presented the accumulated evidence from DOMI Typhoid in case studies to officials in each host country. As a result, policymakers in Pakistan, Indonesia, and Vietnam agreed to introduce school-based typhoid vaccination campaigns on a pilot basis. Results from China uncovered a previously unknown growing incidence rate of paratyphoid A infections in China's Guangxi province, which led to IVI launching its Paratyphoid in China project. [12]
The DOMI Cholera program sought to develop and accelerate the use of an affordable cholera vaccine in cholera-endemic countries. DOMI Cholera operated from five study sites: Matlab, Bangladesh; North Jakarta, Indonesia; Kolkata, India; Beira, Mozambique; and Hue, Vietnam. From these sites, IVI conducted disease burden, economic, and socio-behavioral studies and cholera vaccination campaigns. The studies found a high demand for cholera vaccine and high incidence rates (3-9/1,000) in children five years old and younger. IVI's vaccination campaign in Beira saw more than 44,000 children and adults receive the internationally licensed Dukoral vaccine. In Kolkata, IVI vaccinated more than 67,000 children and adults using an oral cholera vaccine produced by Vietnam's VaBiotech. At the onset of DOMI Cholera, the only internationally licensed cholera vaccine available was Dukoral, but at $90 for the two-dose series, this vaccine was too expensive for public use in many of the poorest developing countries. VaBiotech's cholera vaccine, originally developed by Vietnam's National Institute of Health and Epidemiology following a technology transfer from the University of Gothenburg in Sweden, was not licensed for international use but showed great promise as a low-cost vaccine for the developing world. As a result, the Gates Foundation provided IVI with additional funding to establish the Cholera Vaccine Initiative (CVI) with the goal of reformulating the VaBiotech vaccine for international use. [13]
IVI established the DOMI Shigellosis program with the ultimate goal of accelerating the development and introduction of a safe and protective shigella vaccine to control epidemic and endemic disease. Between 2000 and 2004, the DOMI Shigella program ran disease surveillance sites in six locations across Southeast Asia: Dhaka, Bangladesh; Hebei, China; Karachi, Pakistan and neighboring villages; North Jakarta, Indonesia; Nha Trang, Vietnam; and Saraburi Province, Thailand. The program enhanced understanding of what an effective shigella vaccine will need and established an accurate disease burden in the countries where it operated. The program first evaluated an oral shigella vaccine (SC602) in Bangladesh, but it failed to elicit an immune response. The high disease burden, serotype diversity, and high levels AMR discovered at IVI's surveillance sites underscored the need for a vaccine that protects against all common strains of the disease. As a result, IVI's Division of Laboratory Sciences initiated a multiyear program to sequence the Shigella genome and identify common proteins in different Shigella species that could be used to develop a vaccine against all common strains of the disease. [14]
IVI initiated the Rotavirus Diarrhea Program to provide policymakers in developing countries with the disease burden evidence and economic data needed to ensure the inclusion of rotavirus vaccines in their national immunization programs. Running from 1999 to 2010, the program conducted disease surveillance and economic studies in Cambodia, China, India, Indonesia, Laos, Mongolia, South Korea, Sri Lanka, and Vietnam. In 2007, in collaboration with Vietnam's National Institute of Hygiene and Epidemiology (NIHE), IVI conducted a Phase II trial of GSK's RotaRix rotavirus vaccine in Khanh Hoa, Vietnam. In 2009, in collaboration with NIHE, PATH, and Merck, IVI completed a Phase III trial of Merck's RotaTeq rotavirus vaccine in Nha Trang Vietnam, where it vaccinated 900 infants. [15]
The Pediatric Dengue Vaccine Initiative was a product development partnership launched by IVI to accelerate the introduction of safe and effective dengue vaccines for children in dengue-endemic countries. From 2002 to 2010, PDVI operated in Brazil, Cambodia, Colombia, India, Indonesia, Laos, Malaysia, Mexico, Myanmar, Nicaragua, Sri Lanka, Thailand and Vietnam. PDVI made many contributions to dengue vaccine development, including: [16]
In 2010, PDVI transitioned into the Dengue Vaccine Initiative (DVI). [17]
The successor to PDVI, the Dengue Vaccine Initiative was an IVI-led consortium with the World Health Organization, the Sabin Vaccine Institute, the Initiative for Vaccine Research (IVR), and the International Vaccine Access Center (IVAC) at Johns Hopkins University. DVI continued the work of PDVI and focused on laying the groundwork for dengue vaccine decision-making and vaccine introduction in endemic areas. Each consortium member was responsible for a specific component: World Health Organization – information and guidance documents, and regulatory training activities; Johns Hopkins University – dengue vaccine financing and strategic demand forecasting; and Sabin Vaccine Institute – communications and advocacy. Besides leading the consortium, IVI generated evidence for decision-making such as disease burden, country vaccine introduction cases and a global investment case. From 2010 to 2016, DVI operated in Brazil, Burkina Faso, Cambodia, Colombia, Gabon, India, Kenya, Thailand, and Vietnam. From 2013 to 2015, with funding from Germany's Federal Ministry of Education & Research (BMBF), IVI continued support for preclinical development of dengue vaccines by Brazil's Butantan Institute and Vietnam's VaBiotech. After the 2016 licensure of Sanofi Pasteur's Dengvaxia vaccine, the DVI project came to a close and its IVI staff transitioned to a new project, the Global Dengue & Aedes-Transmitted Disease Consortium (GDAC). [18]
As of January 2019, IVI includes 35 countries and the World Health Organization (WHO) as signatories to its Establishment Agreement: Bangladesh, Bhutan, Brazil, China, Ecuador, Egypt, India, Indonesia, Israel, Jamaica, Kazakhstan Kyrgyzstan, Lebanon, Liberia, Malta, Mongolia, Myanmar, Nepal, Netherlands, Oman, Pakistan, Panama, Papua New Guinea, Peru, Philippines, Republic of Korea, Romania, Senegal, Sri Lanka, Sweden, and the World Health Organization. [19]
IVI partners with corporations, philanthropic organizations, foundations, governments and media organizations from around the world. Major partners include: [20]
Shigellosis is an infection of the intestines caused by Shigella bacteria. Symptoms generally start one to two days after exposure and include diarrhea, fever, abdominal pain, and feeling the need to pass stools even when the bowels are empty. The diarrhea may be bloody. Symptoms typically last five to seven days and it may take several months before bowel habits return entirely to normal. Complications can include reactive arthritis, sepsis, seizures, and hemolytic uremic syndrome.
ATC code J07Vaccines is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup J07 is part of the anatomical group J Antiinfectives for systemic use.
Gastroenteritis, also known as infectious diarrhea, is an inflammation of the gastrointestinal tract including the stomach and intestine. Symptoms may include diarrhea, vomiting, and abdominal pain. Fever, lack of energy, and dehydration may also occur. This typically lasts less than two weeks. Although it is not related to influenza, in the U.S. and U.K., it is sometimes called the "stomach flu".
ICDDR,B is an international health research organisation located in Dhaka, Bangladesh. Dedicated to saving lives through research and treatment, ICDDR,B addresses some of the most critical health concerns facing the world today, ranging from improving neonatal survival to HIV/AIDS. In collaboration with academic and research institutions over the world, ICDDR,B conducts research, training and extension activities, as well as programme-based activities, to develop and share knowledge for global lifesaving solutions.
The National Institute of Virology in Pune, India is an Indian virology research institute and part of the Indian Council of Medical Research (ICMR). It was previously known as 'Virus Research Centre' and was founded in collaboration with the Rockefeller Foundation. It has been designated as a WHO H5 reference laboratory for SE Asia region.
The rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. The vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of the risk of death among young children due to severe diarrhea. Immunizing babies decreases rates of disease among older people and those who have not been immunized.
Mary Lou Clements-Mann was the founder and first Director of the Center for Immunization Research at the Johns Hopkins Bloomberg School of Public Health and is well known for her work in the areas of HIV and influenza vaccine research.
A vaccine-preventable disease is an infectious disease for which an effective preventive vaccine exists. If a person acquires a vaccine-preventable disease and dies from it, the death is considered a vaccine-preventable death.
Institut Pasteur Korea is an infectious disease-focused research institute located in Gyeonggi Province, Rep. of Korea. Its mission is to identify novel molecular targets and discover small molecules by utilizing its proprietary platforms to diagnose, treat and address serious unmet global public health needs.
Naval Medical Research Unit SOUTH, formerly known as Naval Medical Research Unit Six, is a biomedical research laboratory of the U.S. Navy located in Lima, Peru. It is the only U.S. military command located in South America. Its mission is to identify infectious disease threats of military and public health importance and to develop and evaluate interventions and products to mitigate those threats.
Firdausi Qadri is a Bangladeshi scientist with specialization in immunology and infectious disease research. She has worked over 25 years on the development of vaccines for cholera and has expertise on other infectious disease like ETEC, Typhoid, Helicobacter pylori, rotavirus, etc. Currently, she is working as a director for Centre for Vaccine Sciences of International Centre for Diarrhoeal Disease and Research, Bangladesh (ICDDR,B). She also serves as chairperson of the Institute for developing Science and Health initiatives. Her scientific achievements lie in enteric infections and vaccines including Vibrio cholerae and enterotoxigenic Escherichia coli—major causes of severe diarrhea. She has also focused on studying the immune response in Helicobacter pylori infected people in Bangladesh and the responses in patients with typhoid fever as well as vaccinees. The Government of Bangladesh awarded her the Independence Award in 2023.
Ira M. Longini is an American biostatistician and infectious disease epidemiologist.
Pasteur Institute of Iran is a medical research center located in Tehran, Iran. The institute is one of the oldest leading research and public health centers in Iran and the Middle East, established in 1920 following an agreement between the Institute Pasteur of Paris and the Iranian government. The Pasteur Institute of Iran was developed with the help of a land donation from Abdol-Hossein Farmanfarma. Its mission is to support advanced research and to provide innovative programs in basic and applied medical sciences, and production of biopharmaceuticals and diagnostic kits with special emphasis on infectious diseases. It meets the specialized and scientific health demands of the local community and tries to establish a link between applied research and industry. Pasteur Institute is a leading regional facility in the development and manufacture of vaccines. The institute has a total staff of 1300 in its 28 departments and 5 branches in different cities of Iran, which are active in different areas of medical and pharmaceutical biotechnology. There are about 300 PhDs and M.Sc. graduates.
Dengue vaccine is a vaccine used to prevent dengue fever in humans. Development of dengue vaccines began in the 1920s, but was hindered by the need to create immunity against all four dengue serotypes. As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga.
Edward Thomas Ryan is an American microbiologist, immunologist, and physician at Harvard University and Massachusetts General Hospital. Ryan served as president of the American Society of Tropical Medicine and Hygiene from 2009 to 2010. Ryan is Professor of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health, Professor of Medicine at Harvard Medical School, and Director of Global Infectious Diseases at the Massachusetts General Hospital. Ryan's research and clinical focus has been on infectious diseases associated with residing in, immigrating from, or traveling through resource-limited areas. Ryan is a Fellow of the American Society of Microbiology, the American Society of Tropical Medicine and Hygiene, the American College of Physicians, and the Infectious Diseases Society of America.
The Institut Pasteur de Dalat is a vaccine research and production complex in Da Lat, Vietnam.
Vaccination in India includes the use of vaccines in Indian public health and the place of vaccines in Indian society, policy, and research.
Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company based in Hyderabad, which is engaged in drug discovery, drug development, and the manufacture of vaccines, biotherapeutics, pharmaceuticals and healthcare products.
Scott Halstead is an American physician-scientist, virologist and epidemiologist known for his work in the fields of tropical medicine and vaccine development. He is considered one of the world's foremost authorities on viruses transmitted by mosquitoes, including Dengue, Japanese encephalitis, chikungunya and Zika. He was one of the first researchers to identify the phenomenon known as antibody-dependent enhancement (ADE), where the antibodies generated from a first dengue infection can sometimes worsen the symptoms from a second infection.
Inovio COVID-19 vaccine is a COVID-19 vaccine candidate developed by Inovio Pharmaceuticals.